@lauriewired The Neo when Tahoe isn’t crapping the bed with memory leaks really manages to handle running lot on 8GB a lot better than I’d have guessed. The first few weeks I was killing apps to not run into the wall and slowly got out of the habit when nothing bad happened.
@misteaz79 This is only surprising to anyone who has never watched COPS before that from time to time this kind of thing can happen, and could be a consequence of almost anything or nothing at all.
Friday we got multiple submissions to HHS (re: 7-OH) about Dante’s Divine Comedy and Disability Access in Chinese Transit.
Also a Bible verse (Eph. 6:12), and another comment about how Federal scheduling will impact a current Louisiana consumer where it is already Schedule I.
@misteaz79 I’m surprised the article didn’t mention that >2% 7-OH products are illegal to sell in CO and even more illegal in UT if he got it there.
The split into 1/8th or 1/16ths is insane when nothing stops them from selling them in a bottle at lower potency like any other tablet.
@drowner___ I didn’t write it, and honestly neither did the commenters.
The existing product often has extremely poor QA and packaged in ways that are attractive to minors.
Less minor access even if the illicit supply that will remain is marginally “dirtier” is a net improvement.
"This will not protect kids and consumers, but send them searching for other less-safe, unregulated…"
4513/27K (16.6%) HHS comments say this verbatim.
The argument for legal 7-OH that diverted supply is better for kids than illicit supply is not great (and off topic).
@Heaven807436108@misteaz79 There is also no surviving perpetrators to generate ongoing outrage over and feed into 6 months of investigations & trial reports.
Pepper in something controversial you get clicks and people sharing your story, even to criticize it.
Clicks and ads are how they make money.
@DrewTurner73@LelenaPeacock As an example, I can only afford one HMO option, the only one my wife’s employer offers.
Even if my MD is decent, that record is shared across the whole system.
You don’t choose your ER attending. They write “drug problem” or won’t give you PM after a crash it affects things.
@DrewTurner73@LelenaPeacock Unfortunately a lot of folks take a different kind of risk broaching the topic with providers, if they even get non-judgemental evidence-based responses. It being anywhere in the electronic chart can influence future providers they can’t pick across ERs and HMOs.
@DrewTurner73@LelenaPeacock I wasn’t suggesting the risk is automatically lower, but that many perceive it to be lower on the basis of it replacing Rx opioids or illicit ones. That is the end of the analysis for many.
@CarrieCnh12 I use it for chronic pain when my Rx was stopped without warning. It has been extremely helpful with low potential for abuse.
The “7-OH” products DEA have scheduled or given notice of intent are chemically synthesized derivatives with a significantly higher potential for misuse.
A comment to HHS (re: 7-OH): "What scares me most is watching my clients get pushed back toward pills and Suboxone if this rule takes effect."
Problem? The writer (who also uses) practices in Louisiana & 7-OH is already criminal to possess. Fed scheduling won't change LA status.
I took a random sample of 400 entries (1.45%) from 7-OH HHS docket (as of Jul-31).
Only 4 provided any scientific argument/resource for the threshold (Q1). 1 addressed alt. measurement (Q2).
Only 52 of the unsolicited anecdotes & opinions even mentioned any dosage parameters.
@andrewlnye@ulga_filbert Can’t let history get in the way of a good story, like claiming AKA opposed 7-OH due to lost revenue.
Warnings of rising levels ‘16. Their KCPA written ‘18 passed ‘19 sets 2% limit. High 7 products enter the market late ’23 or so, definitely post ‘19.
1st ban succeeds ‘25.
Many HHS comments warn about no tapering window if 7-OH becomes C-I.
DEA took a year to act on the FDA/HHS rec.
DEA gave >30 days from the Notice of Intent.
This was the window. Many wasted it on "hope" when industry (funded) orgs grossly overstated the chance of "beating" it.
@ulga_filbert 3. Mullin doesn’t oversee HHS or DOJ. It is outside his purview.
It would be like the Ag secretary investing in an airline and folks thinking that will unduly affect FAA rulemaking.
Botanic Tonics could sell 7-OH (see 2). They don’t because it is a bad idea.
@ulga_filbert 2. If any vendor was only worried about losing market share/revenue they’d just sell 7-OH. It isn’t hard. They have raw materials, customer base, and distribution. They don’t because it is indefensible in law and drew down state and federal actions endangering both industries.
@ulga_filbert 1. It doesn’t matter how good or bad it is in this context.
Folks are asking DEA to do something DEA can’t do as “compromise” and doing it in off topic submissions to HHS RFI for scientific evidence for some threshold.
A common sentiment to HHS/DEA has been "I would support..." all kinds of regulated marketplace provisions in lieu of scheduling.
DEA cannot setup regulated marketplaces for controlled substances or substances it wants to "less than schedule." Congress never gave them that power.
@DrewTurner73@LelenaPeacock For pain pts it is that they are seen to be replacing, not adding. Most aren't getting explained the mechanics of the rationale about what they were Rx'd from the MD, who either accepted the risk and defended it or declined to Rx it. Too few pts even know what their meds are.